Lexaria Bioscience Corp.
$0.99
▲
20.08%
2026-04-21 07:52:00
lexariabioscience.com
NCM: LEXX
Explore Lexaria Bioscience Corp. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$25.53 M
Current Price
$0.99
52W High / Low
$1.69 / $0.46
Stock P/E
—
Book Value
$0.22
Dividend Yield
—
ROCE
-443.04%
ROE
-1.55%
Face Value
—
EPS
$-0.57
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
7
Beta
0.48
Debt / Equity
2.25
Current Ratio
3.68
Quick Ratio
2.32
Forward P/E
-2.33
Price / Sales
43.39
Enterprise Value
$17.94 M
EV / EBITDA
-1.72
EV / Revenue
34.36
Rating
None
Target Price
$3.75
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Cognition Therapeutics, Inc. | $1.12 | — | $106.33 M | — | -70.77% | -88.59% | $3.83 / $0.22 | $0.39 |
| 2. | Relay Therapeutics, Inc. | $16.4 | — | $3 B | — | -50.82% | -41.12% | $17.32 / $2.53 | $3.26 |
| 3. | Lineage Cell Therapeutics, Inc. | $1.65 | — | $410.99 M | — | -21.52% | -1.05% | $2.09 / $0.4 | $0.18 |
| 4. | Jaguar Health, Inc. | $0.41 | — | $5.34 M | — | -91.43% | -628.65% | $15.48 / $0.31 | $0.85 |
| 5. | Sutro Biopharma, Inc. | $34.58 | — | $572.9 M | — | -106.34% | 435.02% | $34.58 / $5.23 | $-15.43 |
| 6. | AtaiBeckley Inc. | $4.9 | — | $1.47 B | — | -76% | -3.9% | $6.75 / $1.29 | $0.61 |
| 7. | Tiziana Life Sciences Ltd | $1.21 | — | $143.81 M | — | -401.27% | -2.32% | $2.6 / $0.87 | $0.08 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 0.17 M | 0.17 M | 0.17 M | 0.18 M |
| Operating Profit | -1.57 M | -2.69 M | -3.75 M | -2.75 M | -2.69 M |
| Net Profit | -1.6 M | -2.7 M | -3.79 M | -2.71 M | -2.7 M |
| EPS in Rs | -0.06 | -0.11 | -0.15 | -0.11 | -0.11 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.71 M | 0.46 M | 0.23 M | 0.26 M |
| Operating Profit | -11.88 M | -5.75 M | -6.53 M | -6.62 M |
| Net Profit | -11.9 M | -5.8 M | -6.66 M | -7.27 M |
| EPS in Rs | -0.48 | -0.23 | -0.27 | -0.29 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 4.18 M | 8.87 M | 3.08 M | 7.83 M |
| Total Liabilities | 1.57 M | 1.21 M | 0.4 M | 0.2 M |
| Equity | 2.99 M | 8.04 M | 3.04 M | 7.95 M |
| Current Assets | 3.47 M | 7.9 M | 2.15 M | 6.98 M |
| Current Liabilities | 1.49 M | 1.1 M | 0.27 M | 0.19 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -10.45 M | -4.96 M | -5.88 M | -4.88 M |
| Investing CF | -0.24 M | -0.19 M | -0.17 M | -0.18 M |
| Financing CF | 6.05 M | 10.32 M | 1.59 M | -0.04 M |
| Free CF | -10.55 M | -5.15 M | -6.05 M | -5.06 M |
| Capex | -0.1 M | -0.19 M | -0.17 M | -0.18 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 105.24% | -11.43% | — | — |
| Earnings Growth % | 13.05% | 8.31% | — | — |
| Profit Margin % | -1248.25% | -2946.36% | -2846.28% | — |
| Operating Margin % | -1239.16% | -2888.5% | -2591.67% | — |
| Gross Margin % | 98.96% | 86.07% | 71.87% | — |
| EBITDA Margin % | -1222.75% | -2824.23% | -2551.45% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.